Methods to create chemically-induced dimerizing protein systems for regulation of cellular events
Methods to create chemically-induced dimerizing (CID) protein systems and uses thereof are described. The methods utilize antibody binding domain dimerizing proteins. The created systems can be used to regulate cellular events such as gene expression, receptor signaling and cell death to effectuate a variety of clinically relevant treatment outcomes.
1. A method of creating a chemically-induced dimerizing protein system comprising:
selecting:
a cell-permeable small molecule,
an antibody binding domain (AB1) that binds the small molecule to form an AB1/small molecule complex, and
a metatype antibody binding domain (AB2) that binds a portion of AB1 and a portion of the small molecule, but only when AB1 is bound to the small molecule to form an AB1/small molecule complex; and
transfecting a cell to express a first fusion protein comprising AB1 and a first effector molecule; and
a second fusion protein comprising AB2 and a second effector molecule,
wherein upon administration of the small molecule to the cell,
the fusion proteins dimerize, creating the chemically-induced dimerizing protein system.
2. The method of claim 1 , wherein the AB1 and/or AB2 are heavy chain only (VHH) or a single chain variable antibody (scFV).
3. The method of claim 2 , wherein the scFV consists essentially of a variable heavy chain and a variable light chain.
4. The method of claim 1 , further comprising confirming AB2 binding to the AB1/small molecule complex and/or confirming AB1 binding to the small molecule.
5. The method of claim 1 , wherein the AB1 binds to the small molecule with high affinity.
6. The method of claim 1 , wherein the AB2 and/or AB1 are obtained by immunization.
7. The method of claim 1 , further comprising humanizing AB2 and/or AB1.
8. The method of claim 1 , further comprising optimizing the binding affinity between AB1 and the small molecule and/or the binding affinity between AB2 and the AB1/small molecule complex and/or the in vivo half-life of AB2 and/or AB1.
9. The method of claim 7 , further comprising confirming that binding affinity between AB2 and the AB1/small molecule complex and AB1 and the small molecule has not been reduced by the humanizing or optimizing.
10. The method of claim 1 , further comprising attaching the small molecule to a protein or solid substrate.
11. The method of claim 10 , further comprising confirming that AB1 does not bind the protein or solid substrate.
12. The method of claim 6 , wherein the identifying AB2 and/or AB1 comprises:
amplifying cDNA reverse transcribed from RNA from B cells isolated from the animal;
ligating cDNA encoding AB1 or AB2 into a screening vector; and
transfecting the screening vector into cells of a growth colony, wherein the cells of the growth colony are electrocompetent E. coli.
13. The method of claim 12 further comprising screening the transfected cell for AB1 that specifically bind the small molecule with high affinity.
14. The method of claim 1 , wherein the first or second effector molecule is a DNA binding domain protein, a transcription activation domain protein, a transcription repressor domain protein, an intracellular portion of a receptor, an intracellular receptor, a caspase, a kinase, an enzyme, or a protease.
15. The method of claim 1 , further comprising administering the small molecule to the cell.